Vormatrogine not checked
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Focal Epilepsy, Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
- Main trialPhase 3
- “A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)”In the company’s words, NCT07505004 on ClinicalTrials.gov
Other drugs for Focal Epilepsy
- BHV-7000Biohaven · Phase 2/3
- CenobamateSK Life Science, Inc. · Phase 3
- RAP-219Rapport Therapeutics Inc. · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- NRTX-1001Neurona Therapeutics · Phase 1/2
- SPN-817Supernus Pharmaceuticals, Inc. · Phase 2
Coming up2
- Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 May 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Jan 2027 | Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | |
| Phase 3Enrolling by invitation | 31 May 2028 | Clinical Trial of Vormatrigine in Adult Patients With Epilepsy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026